Evaluation of Seaweed Sulfated Polysaccharides As Natural Antagonists Targeting *Salmonella typhi* OmpF: Molecular Docking and Pharmacokinetic Profiling

ARUN KUMAR MALAISAMY (✉ makias191@gmail.com)

ICGEB New Delhi: International Centre For Genetic Engineering and Biotechnology New Delhi

<https://orcid.org/0000-0003-4398-1534>

Mahalakshmi Murugan

Madurai Kamaraj University

Ashok Kumar Vairamuthu

Dr NGP Arts and Science College

Manikka Kubendran Aravind

Madurai Kamaraj University

Sathaiah Gunaseelan

Madurai Kamaraj University

Verma Mohankumar

Madurai Kamaraj University

Balasubramaniam Ashokkumar

Madurai Kamaraj University

Varalakshmi Perumal

Madurai Kamaraj University

Research Article

Keywords: *Salmonella typhi*, Outer membrane protein, Seaweed, Sulfated polysaccharides, Molecular Docking, Carrageenan, Macroalgae, OmpF.

Posted Date: September 2nd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-802349/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background: *Salmonella* belongs to the *Enterobacteriaceae* family, a gram-negative, non-spore-forming, rod-shaped, motile, and pathogenic bacteria that transmit through unhygienic conditions. It is estimated that 21 million new infections arise every year, resulting in approximately 200,000 deaths. It is more prevalent among children, the old aged, and immunocompromised individuals. The frequent usage of classical antimicrobials has begun the increasing emergence of various drug-resistant pathogenic bacterial strains. Hence, this study was intended to evaluate the bioactive seaweed sulfated polysaccharides (SSP) against the ompF (outer membrane porin F) protein target of *Salmonella typhi*. SSP are sulfated compounds with a wide range of biological activities, such as anti-microbial, anti-allergy, anti-cancer, anti-coagulant, anti-inflammation, anti-oxidant, and anti-viral.

Results: In this study, eleven compounds were targeted against *S. typhi* OmpF by molecular docking approach and were compared with two commercially available typhoid medications. The SSP showed good binding affinity compared to commercial drugs, particularly carrageenan/MIV-150, carrageenan lambda, fucoidan, and 3-Phenyllactate, ranked as top antagonists against OmpF. Further, pharmacokinetics and toxicology (ADMET) studies corroborated that SSP possessed drug-likeness and highly progressed in all parameters.

Conclusion: AutoDockTools and Schrodinger's QikProp module results suggest that SSP could be a promising drug for extensively drug-resistant (XDR) *S. typhi*. To our best of knowledge, this is the first report on *in-silico* analysis of SSP against *S. typhi* OmpF. Thus, implying the capabilities of SSP's especially compounds like carrageenans, as a potential anti-microbial agent against *Salmonella typhi* infections. Eventually, advanced studies could corroborate SSPs to the next level of application in the crisis of XDR microbial diseases.

1. Background

Salmonella belongs to the *Enterobacteriaceae* family, a gram-negative, non-spore-forming, rod-shaped, motile, and pathogenic bacteria that transmit through unhygienic conditions. The molecular morphology of *Salmonella* serovars contains O, K, H, and the Vi capsular antigens (<https://salmonellatyphi.org/>). Among these serotypes, *Salmonella enteritidis* and *Salmonella typhi* have significant adverse effects, have been reported to cause severe and occasional life-threatening diseases like typhoid fever, sepsis, vomiting, diarrhea, and gastroenteritis (Gonzalez-Escobedo, et al 2011). It is more prevalent among children, old aged, immunocompromised individuals, and it is estimated that 21 million new infections emerge every year, resulting in approximately 200,000 deaths (Crump, et al 2004). They were primarily contributed by Southeast Asia, Southcentral Asia, Turkey, Morocco, Southern Africa, and Latin America. As there is a hike in travelers worldwide, it has been estimated that the incidence rate of typhoid fever in travelers to high-endemic countries is 3–30 cases per 100,000 travelers (Steffen, et al 1987). The frequent usage of classical antimicrobials has begun the increasing emergence of various drug-resistant pathogenic bacterial strains. An outbreak was reported from 2016 to 2018 in Pakistan; a large typhoid fever resulted in 5,372 XDR (Extensively drug-resistance) typhoid cases transmitted across the country. This XDR strain is only susceptible to azithromycin and ciprofloxacin. Only were preventable by improving the hygienic conditions, improved access to clean water, sanitation, and vaccination and anti-microbial therapy (Chatham-Stephens, K., et al 2019). In the last three decades, research showed the emergence of multidrug-resistant (MDR) *S. typhi*, a huge threat to

humankind. *S. typhi* has acquired resistance against chloramphenicol, ampicillin, trimethoprim-sulfamethoxazole, and they are susceptible to fluoroquinolones, cephalosporins (ceftriaxone), and azalide azithromycin. The phylogeographical analysis of the *S. typhi* shows that H58 lineage is highly associated with the MDR and reduced susceptibility to fluoroquinolones such as ciprofloxacin. As a result of MDR, there is an urge to discover new antibiotics or alternative therapeutics to treat *S. typhi* (Wong V K., et al 2015). At an instant, seaweeds got the researcher's attention to treat infectious diseases because of their abundant availability in nature with major health benefits (Sanjeewa, K. A., et al 2018). Seaweed sulfated polysaccharides (SSP) are a complex group of macromolecules with a wide range of important biological activities, such as anti-microbial, anti-allergy, anti-cancer, anti-coagulant, anti-inflammation, anti-oxidant, and anti-viral properties. SSP is commonly found in all three major groups of seaweeds: brown, green, and red seaweeds. Brown SSPs are fucans, including fucoidan, sargassan, ascophyllan, and glucuronoxylofucan; red SSPs are galactans which are commercially available as agar and carrageenan. Green SSPs are usually available as sulfated heteropolysaccharides including galactose, xylose, arabinose, mannose, glucuronic acid, or glucose (Wu, S. C. 2017). On the other hand, 3-Phenyl lactic acid is also reported as a natural, effective anti-microbial drug against the pathogen *Salmonella* (Zhou et al., 2020).

Molecular docking is a virtual screening tool applied in drug discovery with the best binding affinities to predict macromolecules (target protein) and small molecules (ligand) interactions that predict the molecules' conformation and orientation. Hence, this study was intended to evaluate the bioactive SSP against the OmpF (outer membrane porin F) protein target of *Salmonella typhi*. To the best of our knowledge, this is the first report on sulfated polysaccharides from seaweeds against *S. typhi*. In this present study, the molecular findings of the SSP as a natural antagonist against OmpF of *S. typhi* by in-silico approach with ADMET profiling are performed. This study would help in further understanding the mechanism of action at the molecular level. Eventually, advanced studies could corroborate SSPs to the next level of application in the crisis of XDR microbial diseases.

2. Methods

2.1. Target Preparation

The outer membrane protein (OmpF) of *Salmonella typhi* was chosen as the target, and the structure was retrieved from the Protein Data Bank (PDB ID: 4KR4). The inhibitor and HETATM were removed by the Discovery Studio 2020 (Dassault System BIOVIA) visualization tool and saved as PDB format for further molecular docking studies.

2.2. Ligand Preparation

SSPs were used as a possible anti-bacterial compound (ligand) against OmpF of *S. typhi*. The structure of bioactive SSP compounds and commercially available drugs for typhoid fever were retrieved from the PubChem Database (Table 1) in the format of structure data file (SDF), energy minimization was done using Molecular Mechanics Force Field (MMFF) in PyRx virtual screening tool and saved as PDB format for further molecular docking studies.

2.3. Molecular Docking Studies

The computational studies were carried using AutoDockTools 1.5.6 (ADT) (Scripps Research US) with the extension suite to the Python Molecular Viewer of MGL tools with the Cygwin program. The protein and ligand were imported and preprocessed with the removal of water molecules, addition of polar hydrogens, and merging of non-polar with Kollman and Gasteiger charges. Then the grid parameter file and docking parameter file were prepared. The program was executed on the Cygwin platform using the Lamarckian genetic algorithm (LMA) with 50 independent runs (Arunkumar et al., 2021). The resulting ideal docking outputs were analyzed by the orientation and conformation with the least binding score as best affinity. Further, the molecular interaction and distance were calculated in Discovery Studio visualization tool.

2.4. In silico Pharmacokinetic and Toxicological Profiling

The drug-likeness assessment based on adsorption, distribution, metabolism, excretion, and toxicity (ADMET) actions of SSP compounds in the biological network was computationally evaluated using the QikProp module on Schrodinger's Maestro platform. The pharmaceutically important properties of the substances were predicted, and the physicochemical descriptors were compared with the reference values of the QikProp user manual (v3.5, Schrödinger).

3. Results

The medication for bacterial diseases is becoming increasingly difficult because of the development of antimicrobial drug resistance, especially by Gram-negative bacterial pathogens like *Salmonella* (Pagès., et al 2008). Extensively utilized antibacterial drugs act by hindering cell wall synthesis and binding with target proteins of bacteria. The outer membrane of Gram-negative bacteria provides a protective barrier against toxic compounds and environmental stress. OmpF is an integral membrane protein that functions as a porin, involving in transmembrane ion, nutrient molecules, and waste product transport (Cowan., et al 1995; Delcour., 2009). Various reports have shown that OmpF protein's destruction, mutation is associated with altered drug susceptibility in *Salmonella typhimurium* (Nikaido., 2003; Bredin., et al 2002, 2003; Simonet., et al 2000). As a result, a greater comprehension of how changes in membrane permeability activate bacterial resistance is required to develop further antibiotic treatment approaches (Ziervogel, B. K., & Roux, B. (2013)).

3.1. Molecular Docking Analysis

OmpF porin is a trimeric integral membrane protein responsible for the passive transport of small hydrophilic molecules, such as nutrients and waste products, across the outer membrane. In this study, totally eleven compounds were subjected to the molecular docking study. Among them, eight compounds were SSP, one was 3-Phenyllactate, and two were commercial typhoid drugs namely azithromycin and ciprofloxacin were docked with OmpF of *S. typhi*. The best binding scores were obtained in Carrageenan/MIV-150 with a binding score of -4.61 kcal/mol, followed by Carrageenan-lambda (-4.95 kcal/mol); 3,6-anhydro-D-galactose-2-sulfate (-3.26 kcal/mol) and 3-Phenyllactate (-3.59 kcal/mol). The hydrogen (H bond) interactions are described in Table 1. The two- and three-dimensional molecular interactions of protein-ligand complexes are depicted in Fig. 1–4.

Table 1

Binding energy, inhibition concentration (Ki), interactive residue and bond length of the SSP and commercial typhoid drugs docked against *S. typhi* OmpF.

S. No.	PubChem CID	Compound Name	Binding energy (kcal/mol)	Ki	Interactive residue	Bond Length (Å)
1	11966249	κ-carrageenan	+ 1.91	Nil	A66, I165	4.47, 5.31
2	9907284	Carrageenan/MIV-150	-4.61	416.82μM	R138, K217, Y106, I99	3.81, 4.65, 4.83, 5.29
3	102199625	α-carrageenan	-2.28	21.49mM	N309, P111, D108	(4.41, 4.91), 5.01, (1.88, 1.89)
4	102199626	β-carrageenan	-2.91	7.36mM	Y4, M1, N305, L11	(4.98, 5.47), 4.89, 2.09, 4.83
5	91972149	Carrageenan-lambda	-4.95	235.11μM	Y112	3.77
6	446806	3,6-Anhydro-2-(hydrogen sulfate)-alpha-D-galactopyranose	-3.26	4.10mm	K16, v18	5.48, (2.33, 4.22)
7	92023653	Fucoidan	-3.40	3.22mM	Q38	2.11, 2.32
8	101231953	λ-carrageenan	+ 0.81	Nil	E58	2.33
9	4060207	3-Phenyllactate	-3.59	2.36mM	N166, S167, H163, A66	4.70, 3.66, 2.06, 4.80
10	2764	Ciprofloxacin	-5.28	134.14μM	Q34, M109	3.95, 2.26
11	447043	Azithromycin	-5.91	46.65μM	D102, Y97, K42	1.85, 3.45, 4.55

3.2. *In-silico* Pharmacokinetic and Toxicological Profiling

The investigation of drug passages across the anatomy by computational approach is a superficial tool to predict the pharmacology in complicated biological system. The prediction of functionally indicative descriptions and pharmaceutically pertinent attributes of organic molecules can be meticulously estimated by the QikProp module. The assessment of pharmacokinetics of drug molecule essentially needs to be analyzed prior to implementation of clinical trial. Even highly bioactive compound often fails to other physical and

metabolic factorials. In this work, we have analyzed the peculiarity nature of the nine SSP ligand molecules at various physical and biological criterion. Particularly the adsorption on Caco cell lines, oral adsorption, crossing over the blood brain barrier, skin permeability, donor and acceptor of hydrogen bond, and Lipinski 's rules results are tabulated in Table 2. All the nine SSP ligand molecules exhibited significant rating within specified limitation. Especially the polarizing nature of ligand molecules is an immense need to be disperse over the blood stream. κ -carrageenan exhibited 53.668 cubic angstroms of polarizability whereas 3,6-Anhydro-2-(hydrogen sulfate)- α -D-galactopyranose exhibited 14.888 cubic angstroms that is categorized under recommended values of the QikProp Manual. The molecular interaction of SSP ligand molecules were predicted by the sharing of donor and acceptor hydron bonds in complex biological systems wherein κ -carrageenan showed 10 and 36.9 range of donor and acceptor hydron bonds, respectively which leads to functionally interactive configurations. In contradiction the output of Caco cell permeability of κ -carrageenan was lesser degree (0.006) that falls below the recommended values as shown in Table 2. The highly prominent gut cell (Caco) adsorption was appeared in β -carrageenan, which showed 312.18 in the recommended range of > 25 to < 500 values. The α -carrageenan, κ -carrageenan, carrageenan-lambda and λ -carrageenan were ahead of recommended value in the prediction of blood brain barrier co-efficiency that reveals the sign of crossing over the blood brain barrier. Finally, the determination of route of administration either oral or blood stream was resolved by the human oral adsorption features of drug molecules. Four out of nine SSP ligands such as Carrageenan/MIV-150, β -carrageenan, fucoidan and 3-Phenyllactate showed better results in human oral adsorption. Other SSP's can be administrated through blood stream or improved medicinal formulation for greater oral adsorption. Interestingly, Carrageenan/MIV-150, β -carrageenan and fucoidan compounds passed the criteria's and highly progressed in all parameters (superior range are bolded in Table 2). The results evidenced that the ligand molecules from seaweeds can be successfully employed against *Salmonella typhi* in human system without loss of its anti-microbial activity.

Table 2. ADMET profiling of nine compounds with comparison to Schrodinger's QikProp module.

Where 1: κ -carrageenan, 2: Carrageenan/MIV-150, 3: α -carrageenan, 4: β -carrageenan,

5: Carrageenan-lambda, 6: 3,6-Anhydro-2-(hydrogen sulfate)- α -D-galactopyranose, 7: Fucoidan, 8: Lambda-carrageenan, 9: 3-Phenyllactate.

Parameters	1	2	3	4	5	6	7	8	9
mol MW (130.0–725.0)	790.66	368.36	416.36	336.33	582.47	242.20	242.24	594.52	166.17
Dipole (1.0–12.5)	8.29	11.34	4.86	2.12	9.03	2.53	3.00	6.58	4.28
donorHB (0.0–6.0)	10	2	4	4	8	3	3	6	2
accptHB (2.0–20.0)	36.9	6.25	17.6	15.3	25.6	10.8	9.1	23.9	3.7
QPpolrz (13.0–70.0)	53.66	38.78	32.41	28.70	34.07	14.88	18.76	37.80	17.01
QPlogPw (4.0–45.0)	51.73	13.92	23.94	21.32	37.96	16.05	14.34	32.74	8.53
QPlogPo/w (–2.0–6.5)	-6.74	2.12	-1.89	-1.52	-4.54	-1.65	-0.65	-2.73	1.18
QPlogS (–6.5–0.5)	0.46	-5.60	-1.30	-1.41	-0.23	-0.57	-1.20	-0.19	-1.13
QPlogHERG (below –5)	-1.57	-4.67	-2.49	-3.87	1.36	-0.40	-1.36	1.46	-1.97
QPPCaco (<25 poor; >500 great)	0.006	69.78	9.94	312.18	0.001	18.08	33.45	0.02	118.82
QPlogBB (–3.0–1.2)	-6.65	-1.95	-2.49	-1.36	-5.52	-1.37	-1.36	-4.19	-0.78
QPlogKp (–8.0 – –1.0)	-9.18	-3.94	-5.22	-3.67	-9.66	-5.20	-4.68	-7.35	-3.04
#metab (1–8)	9	5	4	5	4	2	3	3	2
QPlogKh _{sa} (–1.5 to 1.5)	-3.61	-0.05	-1.73	-1.30	-2.58	-1.19	-1.09	-2.49	-0.73
Human Oral Absorption (1to 3)	1	2	2	3	1	2	2	1	2
Human Oral Absorption (%)	0	72.38	20.74	62.63	0	39.75	50.38	0	71.0
PSA (7.0–200.0)	368.68	125.80	171.59	124.42	339.71	131.82	117.91	293.49	70.0

Parameters	1	2	3	4	5	6	7	8	9
Rule Of Five	3	0	1	0	3	0	0	3	0
Rule Of Three	2	0	1	0	1	1	0	1	0
Jm (Kp×MW×S (µg cm ⁻² hr ⁻¹))	0.0015	0.0001	0.1213	2.7412	0.00007	0.4030	0.312	0.0168	7.09

4. Discussion

SSP is an abundant molecule in marine algal system with extended pharmacological applications. There are limited literatures reported for anti *S. typhi* activity from traditional medicinal plants like *Vitex doniana* (root), *Cassia tora* (Leaf), *Alstonia boonei* (bark), *Stachytarpheta jamaicensis* (leaf), and *Carica papaya* (Varsha., et al 2013). Above stated compounds were extracted using hot water, cold water and ethanol which were reported to show good activity in the water-soluble region than ethanol. The aqueous and alcohol extracts of *T. avicennioides*, *M. balsamina*, *C. paniculatum* and *T. guineensis* were effective against strains of multidrug-resistant *S. typhi*, whereas only the aqueous extracts of *M. lucida* and *O. gratissimum* were found to be active against MDR *S. typhi* (Akinyemi, K. O., et al 2005). Similarly, methanolic extract of *Glycyrrhiza glabra* and *Azadirachta indica* have been reported for anti-typhoid activity, broad-spectrum anti-bacterial activity against Gram-positive and Gram-negative bacteria (Somia Gul., et al 2015). Likewise, Eugenol (natural essential oil from clove) (Devi, K. P., et al 2010), Resveratrol (flavonoid obtained from grapes, strawberries, cranberries, peanuts, and other plants) (Lee, W., et al 2017) and *T. belerica* extracts have been reported for bactericidal effect on *S. typhi* (Madani, A., et al 2008). Besides, plant-derived compounds, bacterial byproducts or metabolites also have the potential anti-bacterial activity against *S. typhi*. The 3-Phenyllactate (3-PLA), a metabolite produced from lactic acid bacteria (LAB) *Lactobacillus plantarum* ZJ316 in phenylalanine metabolism is reported to exhibit anti-bacterial activity against *Salmonella* and also as an effective food preservative (Stoyanova, L. G., et al 2012). The 3-PLA is a novel anti-microbial organic acid with a broad anti-bacterial spectrum against Gram-positive, Gram-negative bacteria and also against some fungi. They can impact pH, intracellular osmotic pressure, cell membrane permeability, material transport, cell signal transduction, energy metabolism, or biomacromolecule synthesis (Zhou, Q., et al 2020).

Previous studies have been reported that SSP extracted from marine algae shows potential anti-viral activity against human immunodeficiency virus (HIV), herpes simplex virus (HSV) and cytomegalovirus (CMV) (Witvrouw, et al 1997). Similarly, SSP extracted from *Nothogeniu fastigiata* also showed potent anti-viral activity against HIV, HCMV, HSV and influenza virus (Damonte, E., et al 1994). The reports on marine-sulfated polysaccharide (MSP) extracted from the green macroalga *Ulva armoricana* has anti-bacterial activity against 42 bacterial strains including both Gram-positive and Gram-negative bacteria (Berri, M., et al 2016). Further, anti-bacterial efficacy of fucoidan isolated from *Sargassum wightii* against the shrimp pathogen *Vibrio parahaemolyticus* and seven selected human bacterial pathogens were also reported (Marudhupandi, T., et al 2013). Thus, implying the capabilities of marine sulfated polysaccharides as a potential anti-microbial agent,

particularly seaweed sulfated polysaccharides like carrageenans against *Salmonella typhi* infections. Thus, further in-vitro and in-vivo studies can be looked upon to take these bioactive SSP's to the next level of application in the crisis of XDR microbial diseases.

5. Conclusions

The frequent usage of classical antimicrobials has begun the increasing emergence of various drug-resistant pathogenic bacterial strains like MDR *Salmonella typhi*. In this context, the computational approaches for virtual screening of the natural sulfated polysaccharides of marine algae retrieved from the PubChem database were docked with the outer membrane protein F of *Salmonella typhi* to investigate the ability of the compounds to block the entry of the bacteria by preventing the attachment into the host. The docking results attained strongly suggest that the SSP had shown a better interaction with *S. typhi* OmpF equivalent to commercial leading drugs used for typhoid. Furthermore, among the SSP compounds, Carrageenan/MIV-150 showed the best binding affinity with H-bond interactions with drug-likeness properties. In addition, Carrageenan/MIV-150, β -carrageenan and fucoidan compounds passed the ADMET criteria's and highly progressed in all parameters. Hence, indicating the potentials of marine sulfated polysaccharides as a possible anti-microbial agent, particularly SSP like carrageenans against *Salmonella typhi* infections. Therefore, based on the mechanism of interaction of these ligands with the OmpF target, it needs to be further evaluated by conducting in-vitro studies to confirm their anti-microbial activity against the bacteria. These compounds would be the suitable drug candidates for the treatment of MDR *S. typhi*. Hence, these natural SSPs can be looked upon to the next level of application in the crisis of XDR microbial diseases.

Abbreviations

SSP: Seaweed sulfated polysaccharides; *S. typhi*: *Salmonella typhi*; OmpF: Outer membrane porin F; MDR: Multiple drug-resistance; XDR: Extensively drug-resistance; ADMET (absorption, distribution, metabolism, excretion, and toxicity); CID: Compound ID; ADT: AutoDockTools; PDB: Protein Data Bank.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

The data used and generated during the present study are obtainable from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

Not applicable.

Authors' contributions

The manuscript was written through contributions of all the authors, where, P.V.² designed the experiment; M.A.^{1,4}, M.M.², V.A.K.³, & M.A.K.⁴ conducted the experiments; P.V.², V.M.², and B.A.⁴, analyzed the data; S.G.², M.M.², and P.V.², wrote the manuscript.

Acknowledgments

The authors thank the International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi for ADMET studies using Schrodinger software and DST-PURSE, DST-FIST, UGC-UPE of Madurai Kamaraj University for common facilities.

Authors' information

¹*Transcriptional Regulation Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi - 110067, India.*

²*Department of Molecular Microbiology, School of Biotechnology, Madurai Kamaraj University, Madurai, Tamil Nadu - 625021, India.*

³*Department of Microbiology, Dr. N.G.P Arts and Science College, Coimbatore - 641048, Tamil Nadu, India.*

⁴*Department of Genetic Engineering, School of Biotechnology, Madurai Kamaraj University, Madurai, Tamil Nadu - 625021, India.*

References

1. Akinyemi, K. O., Mendie, U. E., Smith, S. T., Oyefolu, A. O., & Coker, A. O. (2005). Screening of some medicinal plants used in south-west Nigerian traditional medicine for anti-*Salmonella typhi* activity. *Journal of Herbal Pharmacotherapy*, 5(1), 45–60.
2. Arunkumar, M., Gunaseelan, S., Kubendran Aravind, M., Mohankumar, V., Anupam, P., Harikrishnan, M., ... Varalakshmi, P. (2021). Marine algal antagonists targeting 3CL protease and spike glycoprotein of SARS-CoV-2: a computational approach for anti-COVID-19 drug discovery. *Journal of Biomolecular Structure and Dynamics*, 1–28.
3. Berri, M., Slugocki, C., Olivier, M., Helloin, E., Jacques, I., Salmon, H., ... Collen, P. N. (2016). Marine-sulfated polysaccharides extract of *Ulva armoricana* green algae exhibits an anti-microbial activity and stimulates

- cytokine expression by intestinal epithelial cells. *Journal of applied phycology*, 28(5), 2999–3008.
4. Bredin, J., Saint, N., Malléa, M., Dé, E., Molle, G., Pagès, J. M., & Simonet, V. (2002). Alteration of pore properties of *Escherichia coli* OmpF induced by mutation of key residues in anti-loop 3 region. *Biochemical Journal*, 363(3), 521–528.
  5. Bredin, J., Simonet, V., Iyer, R., Delcour, A. H., & Pagès, J. M. (2003). Colicins, spermine and cephalosporins: a competitive interaction with the OmpF eyelet. *Biochemical Journal*, 376(1), 245–252.
  6. Chatham-Stephens, K., Medalla, F., Hughes, M., Appiah, G. D., Aubert, R. D., Caidi, H., ... Nash, J. (2019). Emergence of extensively drug-resistant *Salmonella typhi* infections among travelers to or from Pakistan –United States, 2016–2018. *Morbidity and Mortality Weekly Report*, 68(1), 11.
  7. Cowan, S. W., Garavito, R. M., Jansonius, J. N., Jenkins, J. A., Karlsson, R., König, N., ... Schirmer, T. (1995). The structure of OmpF porin in a tetragonal crystal form. *Structure*, 3(10), 1041–1050.
  8. Crump, J. A., Luby, S. P., & Mintz, E. D. (2004). The global burden of typhoid fever. *Bulletin of the World Health Organization*, 82, 346–353.
  9. Damonte, E., Neyts, J., Pujol, C. A., Snoeck, R., Andrei, G., Ikeda, S., ... Cerezo, A. (1994). Anti-viral activity of a sulfated polysaccharide from the red seaweed *Nothogenia fastigiata*. *Biochemical pharmacology*, 47(12), 2187–2192.
  10. Delcour, A. H. (2009). Outer membrane permeability and antibiotic resistance. *Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics*, 1794(5), 808–816.
  11. Devi, K. P., Nisha, S. A., Sakthivel, R., & Pandian, S. K. (2010). Eugenol (an essential oil of clove) acts as an anti-bacterial agent against *Salmonella typhi* by disrupting the cellular membrane. *Journal of ethnopharmacology*, 130(1), 107–115.
  12. Gonzalez-Escobedo, G., Marshall, J. M., & Gunn, J. S. (2011). Chronic and acute infection of the gall bladder by *Salmonella typhi*: understanding the carrier state. *Nature Reviews Microbiology*, 9(1), 9–14.
  13. <http://www.salmonellatyphi.org/>
  14. Lee, W., & Lee, D. G. (2017). Resveratrol induces membrane and DNA disruption via pro-oxidant activity against *Salmonella typhimurium*. *Biochemical and biophysical research communications*, 489(2), 228–234.
  15. Madani, A., & Jain, S. K. (2008). Anti-Salmonella activity of *Terminalia belerica*: in vitro and in vivo studies.
  16. Marudhupandi, T., & Kumar, T. T. A. (2013). Anti-bacterial effect of fucoidan from *Sargassum wightii* against the chosen human bacterial pathogens. *International Current Pharmaceutical Journal*, 2(10), 156–158.
  17. Nikaido, H. (2003). Molecular basis of bacterial outer membrane permeability revisited. *Microbiology and molecular biology reviews*, 67(4), 593–656.
  18. Pages, J. M., James, C. E., & Winterhalter, M. (2008). The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. *Nature Reviews Microbiology*, 6(12), 893–903.
  19. QikProp, version 3.5, Schrödinger, LLC, New York, NY, 2012.
  20. Sanjeewa, K. A., Kang, N., Ahn, G., Jee, Y., Kim, Y. T., & Jeon, Y. J. (2018). Bioactive potentials of sulfated polysaccharides isolated from brown seaweed *Sargassum* spp in related to human health applications: A

- review. *Food Hydrocolloids*, 81, 200–208.
21. Simonet, V., Malléa, M., & Pagès, J. M. (2000). Substitutions in the eyelet region disrupt cefepime diffusion through the *Escherichia coli* OmpF channel. *Antimicrobial agents and chemotherapy*, 44(2), 311–315.
  22. Somia Gul., Asma Ejaj., Zehra Ashraf. (2015) an Alternative, H. T. *Glycyrrhiza glabra* and *Azadirachta indica* against *Salmonella typhi*: Herbal Treatment as an Alternative Therapy for Typhoid Fever.
  23. Steffen, R., Rickenbach, M., Wilhelm, U., Helminger, A., & Schär, M. (1987). Health problems after travel to developing countries. *Journal of Infectious Diseases*, 156(1), 84–91.
  24. Stoyanova, L. G., Ustyugova, E. A., & Netrusov, A. I. (2012). Anti-bacterial metabolites of lactic acid bacteria: their diversity and properties. *Applied Biochemistry and Microbiology*, 48(3), 229–243.
  25. Varsha, S., Agrawal, R. C., & Sonam, P. (2013). Phytochemical screening and determination of anti-bacterial and anti-oxidant potential of *Glycyrrhiza glabra* root extracts. *Journal of environmental Research and Development*, 7(4A), 1552.
  26. Witvrouw, M., & De Clercq, E. (1997). Sulfated polysaccharides extracted from sea algae as potential anti-viral drugs. *General Pharmacology: The Vascular System*, 29(4), 497–511.
  27. Wong, V. K., Baker, S., Pickard, D. J., Parkhill, J., Page, A. J., Feasey, N. A., ... Edwards, D. J. (2015). Phylogeographical analysis of the dominant multidrug-resistant H58 clade of *Salmonella typhi* identifies inter-and intracontinental transmission events. *Nature genetics*, 47(6), 632–639.
  28. Wu, S. C. (2017). Anti-oxidant activity of sulfated seaweeds polysaccharides by novel assisted extraction. *Solubility of Polysaccharides*; Xu, Z., Ed.; IntechOpen: London, UK, 89–108.
  29. Zhou, Q., Gu, R., Li, P., Lu, Y., Chen, L., & Gu, Q. (2020). Anti-Salmonella mode of action of natural l-phenyl lactic acid purified from *Lactobacillus plantarum* ZJ316. *Applied Microbiology and Biotechnology*, 1–10.
  30. Ziervogel, B. K., & Roux, B. (2013). The binding of antibiotics in OmpF porin. *Structure*, 21(1), 76–87.

Figures

Figure 1

Two-dimensional chemical structure of selected compounds (ligands) retrieved from PubChem database with compound ID.

Figure 2

Molecular interactions of commercially available drugs against *S. typhi* OmpF. Azithromycin 3D interaction (A) & 2D interaction (B); Ciprofloxacin 3D interaction (C) & 2D interaction (D).

Figure 3

Molecular interactions of *S. typhi* OmpF with carrageenan lambda 3D interaction (A) & 2D interaction (B); Carrageenan/MIV-150 3D interaction (C) & 2D interaction (D); 3,6-anhydro-D-galactose-2-sulfate 3D interaction (E) & 2D interaction (F).

Figure 4

Molecular interactions of *S. typhi* OmpF with β -carrageenan 3D interaction (A) & 2D interaction (B); α -carrageenan 3D interaction (C) & 2D interaction (D); λ -carrageenan 3D Interaction (E) & 2D interaction (F).

Figure 5

Molecular interactions of *S. typhi* OmpF with 3-Phenyllactate 3D interaction (A) & 2D interaction (B); Fucoidan 3D interaction (C) & 2D interaction (D); κ -carrageenan 3D interaction (E) & 2D interaction (F).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [graphicalabstract.png](#)